__NUXT_JSONP__("/drugs/Lutetium_Lu_177-Edotreotide", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A radioconjugate consisting of the somatostatin analogue edotreotide labeled with lutetium Lu 177 with potential antineoplastic activities. Lutetium Lu 177-edotreotide binds to somatostatin receptors (SSTRs), with high affinity to type 2 SSTR, present on the cell membranes of many types of neuroendocrine tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to SSTR-positive cells. Edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide (Tyr3-octreotide or TOC) and chelated by the bifunctional, macrocyclic chelating agent dodecanetetraacetic acid (DOTA).",fdaUniiCode:"RGO812Q0C8",identifier:"C88277",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129819","C2124"],synonyms:["177Lu-DOTATOC","177Lu-Edo","177Lu-Edotreotide","EDOTREOTIDE LUTETIUM LU-177","Lutetium 177Lu-Edotreotide","Lutetium Lu 177 DOTA-Tyr3-octreotide",c,"[177LuDOTA]-TOC"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FLutetium_Lu_177-Edotreotide",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Lutetium_Lu_177-Edotreotide","Lutetium Lu 177-Edotreotide","2021-10-30T13:46:45.863Z")));